Noema Pharma Raises $147 Million in Funding

Noema Pharma, a clinical-stage biotech firm based in Switzerland, has successfully closed a Series B extension financing round, raising a total of CHF 130 million (approximately $147 million) with investment from EQT Life Sciences. This funding will be allocated to support four ongoing Phase 2 trials, with data readouts expected in 2025, focusing on treatments for severe pain in trigeminal neuralgia, seizures in tuberous sclerosis complex, Tourette syndrome, and vasomotor symptoms associated with menopause. The funding round attracted existing investors including Forbion, Jeito Capital, and Sofinnova Partners, and follows an initial Series B financing of CHF 103 million announced in March 2023. Ilise Lombardo, CEO of Noema Pharma, emphasized the importance of this financial backing in advancing the company's innovative therapies aimed at addressing high unmet medical needs in CNS disorders. Noema Pharma has developed a strong pipeline since its inception in 2019, reflecting significant investor confidence in its vision and capabilities. The company aims to make a meaningful impact on patients' lives with its neuroscience-based treatments.